Ainos (AIMD) Stock Price, News & Analysis

Company Overview

Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.

Key Stats

• Today's Range: $0.44 to $0.50
• 50-Day Range: $0.44 to $0.64
• 52-Week Range: $0.40 to $4.29
• Volume: 1.21 million shs
• Average Volume: 241,631 shs
• Market Capitalization: $3.86 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Ainos Stock Analysis - MarketRank™

Ainos scored higher than 11% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Ainos.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Ainos has a P/B Ratio of 0.09. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

16.36% of the float of Ainos has been sold short.

Short Interest Ratio / Days to Cover

Ainos has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Ainos has recently decreased by 37.57%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Ainos does not currently pay a dividend.

Dividend Growth

Ainos does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

16.36% of the float of Ainos has been sold short.

Short Interest Ratio / Days to Cover

Ainos has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Ainos has recently decreased by 37.57%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.8 / 5
• News Sentiment: -0.52

News Sentiment

Ainos has a news sentiment score of -0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.37 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Ainos this week, compared to 0 articles on an average week.

MarketBeat Follows

Only 1 people have added Ainos to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Ainos insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.39% of the stock of Ainos is held by insiders. A high percentage of insider ownership can be a sign of company health.

AIMD Stock Analysis - Frequently Asked Questions

How have AIMD shares performed this year?

Ainos' stock was trading at $2.05 at the beginning of 2024. Since then, AIMD shares have decreased by 76.6% and is now trading at $0.4798.
View the best growth stocks for 2024 here.

When did Ainos' stock split?

Shares of Ainos reverse split on Thursday, December 14th 2023. The 1-5 reverse split was announced on Thursday, December 14th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, December 14th 2023. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

When did Ainos IPO?

Ainos (AIMD) raised $3 million in an IPO on Tuesday, August 9th 2022. The company issued 800,000 shares at $4.25 per share. Maxim Group acted as the underwriter for the IPO and Brookline Capital Markets was co-manager.

How do I buy shares of Ainos?

Shares of AIMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Ainos own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Ainos investors own include Broadcom (AVGO), NVIDIA (NVDA), Arista Networks (ANET), e.l.f. Beauty (ELF), Disc Medicine (IRON), Jabil (JBL) and Adobe (ADBE).

Company Calendar

• Today: 11/10/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 3/14/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:AIMD
• Previous Symbol: NASDAQ:AIMD
• CUSIP: N/A
• CIK: 1014763
• Web: www.ainos.com
• Phone: 858-869-2986
• Fax: 806-376-9301
• Employees: 46
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-13,770,000.00
• Net Margins: -15,348.14%
• Pretax Margin: -23,382.50%
• Return on Equity: -71.35%
• Return on Assets: -49.83%

Debt

• Debt-to-Equity Ratio: 0.43
• Current Ratio: 1.48
• Quick Ratio: 1.45

Sales & Book Value

• Annual Sales: $65,122.00
• Price / Sales: 59.27
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.23 per share
• Price / Book: 0.09

Miscellaneous

• Outstanding Shares: 8,045,000
• Free Float: 7,209,000
• Market Cap: $3.86 million
• Optionable: Not Optionable
• Beta: 1.40